Latest Amyloid precursor protein secretase Stories
MetLife Foundation today announced the recipients of its 2013 Awards for Medical Research in Alzheimer’s Disease: Yueming Li, Ph.D., member and professor, Sloan-Kettering Institute and director and professor, Graduate Program in Pharmacology, Weill Medical College of Cornell University, and Lennart Mucke, M.D., director, Gladstone Institute of Neurological Disease, Joseph B. Martin Distinguished Professor of Neuroscience and professor of Neurology, University of California, San...
NEW YORK, Dec. 4, 2012 /PRNewswire-USNewswire/ -- The Fisher Center for Alzheimer's Research Foundation (ALZinfo.org) today announced it has received the highest 4-star rating for the second consecutive year from Charity Navigator's, the nation's premier charity evaluator. Only 17% of the charities rated by Charity Navigator have received 2 or more consecutive 4-star evaluations, indicating that Fisher Center for Alzheimer's Research Foundation outperforms most other charities in...
Scientists from VIB and KU Leuven have discovered a new target molecule for the development of a treatment against Alzheimer's disease. There is currently no cure for this disease. Many candidate drugs fail because they also target proteins essential to life. This discovery from Leuven could form a target for a treatment against Alzheimer's disease with fewer side effects and that suppresses the very first symptoms of the disease. This research will be published in the leading journal Nature...
CAMBRIDGE, Mass., July 18, 2012 /PRNewswire/ -- Satori Pharmaceuticals, a company dedicated to developing life-changing therapeutics for Alzheimer's disease (AD), announced today that its lead compound, a gamma-secretase modulator (GSM), is efficacious in preclinical models following single or multi-day dosing. This oral presentation, as well as two poster presentations related to the characteristics of Satori's GSMs, was presented at the Alzheimer's Association International...
Connie K. Ho for redOrbit.com - Your Universe Online 5 million. That’s the number of people in the U.S. suffering from Alzheimer’s disease, according to a recent CNN article. Scientists recently announced that they had discovered a gene that fights Alzheimer’s. This is a positive step forward as the gene could help develop treatments to fight the disorder. In the journal Nature, researchers explained how the gene that caused an early form of Alzheimer’s could also be created to...
Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the protease cathepsin B (CatB) as a target for improving memory deficits and reducing the pathology of Alzheimer's disease (AD) in an animal model representative of most AD patients. The study has been published in the online edition of the Journal of Alzheimer's Disease. According to...
CAMBRIDGE, Mass., Feb. 23, 2012 /PRNewswire/ -- Satori(TM) Pharmaceuticals, a developer of life changing therapeutics for Alzheimer's disease (AD), today announced that it has raised an additional $15 million in financing. Current investors InterWest Partners, New Enterprise Associates Inc. (NEA) and Prospect Venture Partners co-led the round. Prior to this round, Satori had raised a total of $25 million in financing which has allowed the Company to select a group of lead compounds...
Sluggish recycling of a protein-slicing enzyme could promote Alzheimer's disease, according to a study published online on November 21 in The Journal of Cell Biology (www.jcb.org). Abeta, the toxic protein that accumulates in the brains of Alzheimer's patients, is formed when enzymes cut up its parental protein, known as amyloid precursor protein. One of those enzymes is beta-secretase or BACE1. BACE1 cycles between the Golgi apparatus and the plasma membrane, traveling through endosomes...
Nutri-Med Logic Corp discusses the role of R-Alpha Lipoic and Omega-3 as a vehicle to improve the homeostasis. It has been suggested that redox imbalance causes alteration in the production of the protein Amyloid Beta pathways (gamma vs. alpha secretase) and that could be translated to the wrong vs. right amyloid protein synthesis in cases of Alzheimer / cognitive decline (PRWEB) August 06, 2011 Nutri-Med Logic Corp: Benefits of proper nutrition such as R-Alpha Lipoic and Omega-3 in...
CAMBRIDGE, Mass., July 18, 2011 /PRNewswire/ -- Satori(TM) Pharmaceuticals today announced the presentation of two posters at the Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) taking place in Paris, France, July 16-21, 2011. Both posters illuminate the unique biological activity associated with Satori's approach to the treatment of Alzheimer's disease. The posters were titled, "Gamma-secretase modulators do not show a potency shift in high expressing model...
